利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.027 秒)

    Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes
    1.
    发明申请
    Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes 审中-公开
    用作糖尿病治疗中的GLK激活剂的杂芳基苯甲酰胺衍生物

    公开(公告)号：US20090253676A1

    公开(公告)日：2009-10-08

    申请号：US12336170

    申请日：2008-12-16

    申请人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    发明人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    IPC分类号： A61K31/4155 ,  C07D403/12 ,  A61K31/497 ,  C07D413/12 ,  A61K31/4245 ,  A61P3/10

    CPC分类号： C07D277/46 ,  C07D231/40 ,  C07D285/08 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

    摘要： Compounds of Formula (I): wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物：其中：R1是羟甲基; R2选自-C（O）NR4R5，-SO2NR4R5，-S（O）pR4和HET-2; HET-1是5-或6-元，任选取代的C连接的杂芳基环; HET-2是4-，5-或6-元C-或N-连接的任选取代的杂环基环; R 3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基; R4选自例如氢，任选取代的（1-4C）烷基和HET-2; R5是氢或（1-4C）烷基; 或R 4和R 5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统; HET-3是例如任选取代的N-连接的，4,5或6元饱和或部分不饱和的杂环基环; p是（每次出现时独立）0,1或2; m为0或1; n为0,1或2; 条件是当m为0时，n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Benzamide Derivatives and Their Use as Glucokinase Activating Agents
    2.
    发明申请
    Benzamide Derivatives and Their Use as Glucokinase Activating Agents 审中-公开
    苯甲酰胺衍生物及其作为葡萄糖激酶活化剂的用途

    公开(公告)号：US20080280872A1

    公开(公告)日：2008-11-13

    申请号：US10588334

    申请日：2005-02-15

    申请人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    发明人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    IPC分类号： A61K31/427 ,  C07D277/46 ,  A61K31/426 ,  C07D403/14 ,  C07D413/12 ,  A61P3/10 ,  A61K31/4245 ,  A61K31/496 ,  C07D417/12

    CPC分类号： C07D487/08 ,  C07D231/40 ,  C07D277/46 ,  C07D403/12 ,  C07D417/12

    摘要： Compounds of Formula (I): wherein: R1 is methoxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物：其中：R 1是甲氧基甲基; R 2选自-C（O）NR 4 R 5，-SO 2 NR 2， 4个，5个，-S（O）4个S 4和4个HET-2; HET-1是5-或6-元，任选取代的C连接的杂芳基环; HET-2是4-，5-或6-元C-或N-连接的任选取代的杂环基环; R 3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基; R 4选自例如氢，任选取代的（1-4C）烷基和HET-2; R 5是氢或（1-4C）烷基; 或R 4和R 5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系; HET-3是例如任选取代的N-连接的，4,5或6元饱和或部分不饱和的杂环基环; p是（每次出现时独立）0,1或2; m为0或1; n为0,1或2; 条件是当m为0时，n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators
    3.
    发明申请
    Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators 审中-公开
    可用作葡萄糖激酶（glk）激活剂的苯甲酰氨基吡啶羧酸衍生物

    公开(公告)号：US20090062351A1

    公开(公告)日：2009-03-05

    申请号：US10579782

    申请日：2004-12-02

    申请人： Peter William Rodney Caulkett ,  Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    发明人： Peter William Rodney Caulkett ,  Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    IPC分类号： A61K31/44 ,  C07D213/72 ,  A61P3/00

    CPC分类号： C07D213/80

    摘要： A compound of Formula (I): Formula (I) wherein: R1 is selected from hydrogen and C1-4alkyl; R2 is selected from: R4—C(R5aR5b)—, R4═C(R6)— and R7aC(R7b)═C(R6)—; R3X— is selected from methyl, methoxymethyl and; R4 is selected from (optionally substituted) C1-4alkyl, phenyl, C3-6cycloalkyl and heteroaryl; R5a and R5b are independently selected from hydrogen, fluoro and C1-4alkyl; R6 is selected from hydrogen and C1-4alkyl; R7a and R7b are optionally substituted C1-4alkyl; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物：式（I）其中：R 1选自氢和C 1-4烷基; R2选自：R4-C（R5aR5b） - ，R4-C（R6） - 和R7aC（R7b）-C（R6） - ; R3X-选自甲基，甲氧基甲基和 R 4选自（任选取代的）C 1-4烷基，苯基，C 3-6环烷基和杂芳基; R5a和R5b独立地选自氢，氟和C1-4烷基; R6选自氢和C 1-4烷基; R7a和R7b是任选取代的C 1-4烷基; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Compounds
    4.
    发明申请
    Compounds 审中-公开
    化合物

    公开(公告)号：US20080312207A1

    公开(公告)日：2008-12-18

    申请号：US10588315

    申请日：2005-02-15

    申请人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    发明人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    IPC分类号： A61K31/397 ,  C07D417/12 ,  A61K31/496 ,  C07D277/20 ,  A61K31/426 ,  C07D413/12 ,  A61K31/454 ,  A61K31/422 ,  C07D405/12 ,  A61K31/4155 ,  C07D403/12

    CPC分类号： C07D213/75 ,  C07D231/40 ,  C07D241/20 ,  C07D263/48 ,  C07D277/46 ,  C07D285/135 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12

    摘要： Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from —C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C) alkyl and HET-2; R5 is hydrogen or (1-4C) alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物，其中：R 1是甲基; R2选自-C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2; HET-1是5-或6-元，任选取代的C连接的杂芳基环; HET-2是4-，5-或6-元C-或N-连接的任选取代的杂环基环; R 3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基; R4选自例如氢，任选取代的（1-4C）烷基和HET-2; R5是氢或（1-4C）烷基; 或R 4和R 5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统; HET-3是例如任选取代的N-连接的，4,5或6元饱和或部分不饱和的杂环基环; p是（每次出现时独立）0,1或2; m为0或1; n为0,1或2; 条件是当m为0时，n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity
    5.
    发明申请
    Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity 审中-公开
    苯氧基苯甲酰胺化合物在治疗2型糖尿病和肥胖中的应用

    公开(公告)号：US20080280874A1

    公开(公告)日：2008-11-13

    申请号：US11665163

    申请日：2005-10-11

    申请人： Craig Johnstone ,  Darren Mckerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    发明人： Craig Johnstone ,  Darren Mckerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    IPC分类号： A61K31/397 ,  C07D231/10 ,  A61P3/10 ,  A61K31/415

    CPC分类号： C07D213/80 ,  C07D231/40 ,  C07D403/12

    摘要： Compounds of Formula (I): wherein: R1 is methoxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物：其中：R 1是甲氧基甲基; R 2选自-C（O）NR 4 R 5，-SO 2 NR 2， 4个，5个，-S（O）4个S 4和4个HET-2; HET-1是5-或6-元，任选取代的C连接的杂芳基环; HET-2是4-，5-或6-元C-或N-连接的任选取代的杂环基环; R 3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基; R 4选自例如氢，任选取代的（1-4C）烷基和HET-2; R 5是氢或（1-4C）烷基; 或R 4和R 5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系; HET-3是例如任选取代的N-连接的，4,5或6元饱和或部分不饱和的杂环基环; p是（每次出现时独立）0,1或2; m为0或1; n为0,1或2; 条件是当m为0时，n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Heteroaryl benzamide derivatives as GLK activators
    6.
    发明授权
    Heteroaryl benzamide derivatives as GLK activators 失效
    杂芳基苯甲酰胺衍生物作为GLK活化剂

    公开(公告)号：US07745475B2

    公开(公告)日：2010-06-29

    申请号：US11628448

    申请日：2005-06-01

    申请人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    发明人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike ,  Michael James Waring

    IPC分类号： A01N43/56 ,  C07D233/00

    CPC分类号： C07D277/46 ,  C07D231/40 ,  C07D285/08 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

    摘要： Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物，其中：R1是羟甲基; R2选自-C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2; HET-1是5-或6-元，任选取代的C连接的杂芳基环; HET-2是4-，5-或6-元C-或N-连接的任选取代的杂环基环; R 3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基; R4选自例如氢，任选取代的（1-4C）烷基和HET-2; R5是氢或（1-4C）烷基; 或R 4和R 5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统; HET-3是例如任选取代的N-连接的，4,5或6元饱和或部分不饱和的杂环基环; p是（每次出现时独立）0,1或2; m为0或1; n为0,1或2; 条件是当m为0时，n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Chemical compounds
    7.
    发明申请
    Chemical compounds 审中-公开
    化合物

    公开(公告)号：US20090018157A1

    公开(公告)日：2009-01-15

    申请号：US10579552

    申请日：2004-11-25

    申请人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    发明人： Craig Johnstone ,  Darren McKerrecher ,  Kurt Gordon Pike

    IPC分类号： A61K31/443 ,  A61P3/04 ,  A61P3/10 ,  C07D405/12 ,  A61K31/4433

    CPC分类号： C07D405/12

    摘要： Compounds of Formula (I) wherein: R1—X— is selected from: methyl, methoxymethyl and Formula (X); R2 is selected from hydrogen, methyl, chloro and fluoro; n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）的化合物，其中：R 1 -X-选自：甲基，甲氧基甲基和式（X）; R2选自氢，甲基，氯和氟; n为1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。

    Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators
    9.
    发明申请
    Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators 审中-公开
    可用作葡萄糖激酶（Glk）激活剂的苯甲酰基氨基吡啶羧酸衍生物

    公开(公告)号：US20070255062A1

    公开(公告)日：2007-11-01

    申请号：US10579337

    申请日：2004-11-25

    申请人： Craig Johnstone ,  Darren Mckerrecher ,  Kurt Pike

    发明人： Craig Johnstone ,  Darren Mckerrecher ,  Kurt Pike

    IPC分类号： A61K31/44 ,  A61P3/10 ,  C07D211/72

    CPC分类号： C07D213/80

    摘要： Compounds of Formula: (I); wherein: R1 is selected from: fluoro, chloro, C1-3alkyl and C1-3alkoxy; R2—X— is selected from: methyl, methoxymethyl and Formula: (X); n is 0,1 or 2; or a salt, pro-drug or solvate thereof are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

    摘要翻译： 式（I）化合物： 其中：R 1选自：氟，氯，C 1-3烷基和C 1-3烷氧基; R 2 -X-选自：甲基，甲氧基甲基和式：（X）; n为0,1或2; 或其盐，前药或溶剂化物。 还描述了它们用作GLK活化剂，含有它们的药物组合物及其制备方法。